Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.43 |
| ▸ | CDK9 | P50750 | 2/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA6 | P23280 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.40 |
| ▸ | PYGL | P06737 | 1/20 | 0.39 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.38 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12389802 | 0.91 | LMNA (0.47) | LMNAHTTMAPK1RAB9ACCNT1 | |
| SCHEMBL12389781 | 0.90 | MAPK14 (0.48) | LMNARAB9ACCNT1CDK9MAPK14 | |
| SCHEMBL12389015 | 0.87 | LMNA (0.49) | LMNAHTTMAPK1CA12CA1 | |
| SCHEMBL12390182 | 0.87 | SRD5A2 (0.46) | LMNAHTTMAPK1RAB9ACA12 | |
| SCHEMBL12389091 | 0.86 | SRD5A1 (0.48) | LMNAHTTMAPK1RAB9ACA12 | |
| SCHEMBL12390118 | 0.85 | MRGPRX4 (0.45) | LMNAHTTMAPK1RAB9ACA12 | |
| SCHEMBL12389848 | 0.85 | SLC9A1 (0.43) | HTR7 | |
| SCHEMBL12365086 | 0.84 | MAPK14 (0.43) | MAPK14SRD5A1SRD5A2ALDH1A1L3MBTL1 | |
| SCHEMBL12389912 | 0.84 | LMNA (0.45) | LMNAHTTMAPK1RAB9AMAPK14 | |
| SCHEMBL12365411 | 0.84 | MAPK14 (0.50) | LMNAMAPK14CA1CA2SRD5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | LMNA 3515/4885HTT 335/4885MAPK1 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.